<DOC>
	<DOC>NCT02927301</DOC>
	<brief_summary>This study is designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with Stage IB, II, or IIIA NSCLC who are eligible for surgical resection with curative intent. Neoadjuvant therapy will consist of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy will consist of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy.</brief_summary>
	<brief_title>A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Pathologically documented Stage IB, II, or IIIA NSCLC and eligible for surgical resection with curative intent Adequate pulmonary and cardiac function Available biopsy of primary tumor with adequate samples Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate hematologic and endorgan function Agreement to remain abstinent or use appropriate contraception, among women of childbearing potential NSCLC that is clinically tumor size T3 by virtue of multiple tumor nodules within the same lobe Any prior therapy for lung cancer Prior treatment with antiPD1 or PDL1 therapies Major surgery within 28 days prior to Day 1 of Cycle 1 Malignancies other than NSCLC within 3 years prior to Day 1 of Cycle 1 except curatively treated malignancies with a negligible risk of metastasis or death History or risk of autoimmune disease Hepatitis B or C or human immunodeficiency virus (HIV) infection Administration of live attenuated vaccines within 4 weeks before Day 1 of Cycle 1 Severe infections within 4 weeks prior to Day 1 of Cycle 1 Treatment with an investigational agent within 4 weeks or five halflives prior to Day 1 of Cycle 1 History of severe hypersensitivity to chimeric or humanized antibodies or fusion proteins Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>